{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:49Z","timestamp":1791340129767,"version":"4.3.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,12]]},"abstract":"<jats:p>The JAK2V617F mutation has been identified in most cases of Ph-negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Expression of JAK2V617F results in constitutive activation of multiple signaling molecules\/pathways. However, the key signaling downstream of JAK2V617F required for transformation and induction of MPNs remains elusive. Using a mouse genetic strategy, we show here that Stat5 is absolutely required for the pathogenesis of PV induced by Jak2V617F. Whereas expression of Jak2V617F in mice resulted in all the features of human PV, including an increase in red blood cells, hemoglobin, hematocrit, white blood cells, platelets, and splenomegaly, deletion of Stat5 in the Jak2V617F knockin mice normalized all the blood parameters and the spleen size. Furthermore, deletion of Stat5 completely abrogated erythropoietin (Epo)\u2013independent erythroid colony formation evoked by Jak2V617F, a hallmark feature of PV. Re-expression of Stat5 in Stat5-deficient Jak2V617F knockin mice completely rescued the defects in transformation of hematopoietic progenitors and the PV phenotype. Together, these results indicate a critical function for Stat5 in the pathogenesis of PV. These findings also provide strong support for the development of Stat5 inhibitors as targeted therapies for the treatment of PV and other JAK2V617F-positive MPNs.<\/jats:p>","DOI":"10.1182\/blood-2011-03-345215","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T02:08:55Z","timestamp":1323137335000},"page":"3539-3549","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":119,"title":["Critical requirement for Stat5 in a mouse model of polycythemia vera"],"prefix":"10.1182","volume":"119","author":[{"given":"Dongqing","family":"Yan","sequence":"first","affiliation":[{"name":"Departments of Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hutchison","sequence":"additional","affiliation":[{"name":"Pathology, State University of New York Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam","family":"Mohi","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7037","key":"2019111814262741100_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"4","key":"2019111814262741100_B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"2019111814262741100_B3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"2019111814262741100_B4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111814262741100_B5","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera.","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"issue":"17","key":"2019111814262741100_B6","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111814262741100_B7","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111814262741100_B8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"23","key":"2019111814262741100_B9","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease.","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"2019111814262741100_B10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"},{"issue":"8","key":"2019111814262741100_B11","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111814262741100_B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"2019111814262741100_B13","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111814262741100_B14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knockin mice.","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111814262741100_B15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiologic Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111814262741100_B16","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knockin mouse model of JAK2 V617F-positive essential thrombocythemia.","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111814262741100_B17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis.","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111814262741100_B18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111814262741100_B19","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","article-title":"STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.","volume":"285","author":"Funakoshi-Tago","year":"2010","journal-title":"J Biol Chem"},{"issue":"18","key":"2019111814262741100_B20","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1128\/MCB.24.18.8037-8047.2004","article-title":"Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.","volume":"24","author":"Cui","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"5229","key":"2019111814262741100_B21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1126\/science.7660125","article-title":"Inducible gene targeting in mice.","volume":"269","author":"K\u00fchn","year":"1995","journal-title":"Science"},{"issue":"2","key":"2019111814262741100_B22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","article-title":"Prognostic, therapeutic and mechnistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.","volume":"7","author":"Mohi","year":"2005","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111814262741100_B23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.stem.2007.07.005","article-title":"Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy.","volume":"1","author":"Pronk","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"24","key":"2019111814262741100_B24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera.","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111814262741100_B25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood-2007-12-127480","article-title":"Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression.","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111814262741100_B26","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders.","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111814262741100_B27","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML.","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111814262741100_B28","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-07-1005","article-title":"Targeting Ras in myeloid leukemias.","volume":"14","author":"Braun","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111814262741100_B29","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"issue":"2","key":"2019111814262741100_B30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1073\/pnas.0307203101","article-title":"Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.","volume":"101","author":"Braun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111814262741100_B31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI20476","article-title":"Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.","volume":"113","author":"Chan","year":"2004","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111814262741100_B32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL.","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"issue":"7","key":"2019111814262741100_B33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.febslet.2011.02.032","article-title":"Differential biologic activity of disease-associated JAK2 mutants.","volume":"585","author":"Zou","year":"2011","journal-title":"FEBS Lett"},{"issue":"4","key":"2019111814262741100_B34","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/emboj\/17.4.1006","article-title":"IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways.","volume":"17","author":"O'Farrell","year":"1998","journal-title":"EMBO J"},{"issue":"31","key":"2019111814262741100_B35","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1038\/sj.onc.1205592","article-title":"Overexpression of a dominant negative form of STAT3 selectively impairs hematopoietic stem cell activity.","volume":"21","author":"Oh","year":"2002","journal-title":"Oncogene"},{"issue":"8","key":"2019111814262741100_B36","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood-2011-01-331157","article-title":"SHP2 tyrosine phosphatase stimulates CEBPA gene expression to mediate cytokine-dependent granulopoiesis.","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111814262741100_B37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/immu.200310005","article-title":"Transgenic mice with hematopoietic and lymphoid specific expression of Cre.","volume":"33","author":"de Boer","year":"2003","journal-title":"Eur J Immunol"},{"issue":"4","key":"2019111814262741100_B38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gene.10161","article-title":"VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages.","volume":"34","author":"Georgiades","year":"2002","journal-title":"Genesis"},{"issue":"5","key":"2019111814262741100_B39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0092-8674(00)81444-0","article-title":"Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.","volume":"93","author":"Teglund","year":"1998","journal-title":"Cell"},{"issue":"2","key":"2019111814262741100_B40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-8674(00)81013-2","article-title":"Fetal anemia and apoptosis of red cell progenitors in Stat5a\u2212\/\u22125b\u2212\/\u2212 mice: a direct role for Stat5 in Bcl-X(L) induction.","volume":"98","author":"Socolovsky","year":"1999","journal-title":"Cell"},{"issue":"3","key":"2019111814262741100_B41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia.","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"20","key":"2019111814262741100_B42","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1182\/blood-2008-09-181107","article-title":"Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement.","volume":"113","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111814262741100_B43","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice.","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111814262741100_B44","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.","volume":"107","author":"Hoelbl","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111814262741100_B45","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells.","volume":"108","author":"Garcon","year":"2006","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/15\/3539\/1496685\/zh801512003539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/15\/3539\/1496685\/zh801512003539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:26:47Z","timestamp":1574087207000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/15\/3539\/105562\/Critical-requirement-for-Stat5-in-a-mouse-model-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,12]]},"references-count":45,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-345215","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.716748320.793458697","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.716748320.792103377","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,12]]}}}